BioPharmSignal logoBioPharmSignal

Biotech News

Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig

Coherus BioSciences, Inc. (CHRS)Coherus BioSciences, Inc.2026-06-25 13:46 ESTCompany update

REDWOOD CITY, Calif., February 5, 2026 -- Coherus Oncology, Inc. (NASDAQ: CHRS) announced today a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell

Open original release

Related news

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology to Participate in Upcoming Investor Conferences

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

CHRSCoherus BioSciences, Inc.2026-06-25 13:46 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

View all latest news

Coherus BioSciences, Inc.

Coherus BioSciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

CHRSCoherus BioSciences, Inc.2026-06-26 08:50 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

CHRSCoherus BioSciences, Inc.2026-06-26 08:50 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-06-26 08:50 EST

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

CHRSCoherus BioSciences, Inc.2026-06-26 08:50 EST

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

CHRSCoherus BioSciences, Inc.2026-06-26 08:50 EST

Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination with Pasritamig

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States